全文获取类型
收费全文 | 5530篇 |
免费 | 494篇 |
国内免费 | 46篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 266篇 |
妇产科学 | 63篇 |
基础医学 | 649篇 |
口腔科学 | 133篇 |
临床医学 | 619篇 |
内科学 | 1074篇 |
皮肤病学 | 95篇 |
神经病学 | 357篇 |
特种医学 | 448篇 |
外科学 | 680篇 |
综合类 | 158篇 |
一般理论 | 3篇 |
预防医学 | 508篇 |
眼科学 | 145篇 |
药学 | 338篇 |
1篇 | |
中国医学 | 10篇 |
肿瘤学 | 510篇 |
出版年
2023年 | 28篇 |
2022年 | 52篇 |
2021年 | 110篇 |
2020年 | 63篇 |
2019年 | 123篇 |
2018年 | 105篇 |
2017年 | 73篇 |
2016年 | 108篇 |
2015年 | 127篇 |
2014年 | 154篇 |
2013年 | 255篇 |
2012年 | 277篇 |
2011年 | 265篇 |
2010年 | 206篇 |
2009年 | 181篇 |
2008年 | 238篇 |
2007年 | 254篇 |
2006年 | 264篇 |
2005年 | 252篇 |
2004年 | 237篇 |
2003年 | 247篇 |
2002年 | 186篇 |
2001年 | 195篇 |
2000年 | 147篇 |
1999年 | 135篇 |
1998年 | 134篇 |
1997年 | 112篇 |
1996年 | 98篇 |
1995年 | 86篇 |
1994年 | 68篇 |
1993年 | 80篇 |
1992年 | 70篇 |
1991年 | 87篇 |
1990年 | 63篇 |
1989年 | 93篇 |
1988年 | 78篇 |
1987年 | 83篇 |
1986年 | 51篇 |
1985年 | 60篇 |
1984年 | 38篇 |
1983年 | 43篇 |
1982年 | 37篇 |
1981年 | 31篇 |
1980年 | 37篇 |
1978年 | 40篇 |
1977年 | 44篇 |
1976年 | 34篇 |
1975年 | 35篇 |
1974年 | 28篇 |
1972年 | 32篇 |
排序方式: 共有6070条查询结果,搜索用时 15 毫秒
81.
82.
Deterministic dynamic compartmental transmission models (DDCTMs) of human papillomavirus (HPV) transmission have been used in a number of studies to estimate the potential impact of HPV vaccination programs. In most cases, the models were built under the assumption that an individual who cleared HPV infection develops (life-long) natural immunity against re-infection with the same HPV type (this is known as SIR scenario). This assumption was also made by two Australian modelling studies evaluating the impact of the National HPV Vaccination Program to assist in the health-economic assessment of male vaccination. An alternative view denying natural immunity after clearance (SIS scenario) was only presented in one study, although neither scenario has been supported by strong evidence. Some recent findings, however, provide arguments in favour of SIS. 相似文献
83.
84.
Rainbow K. Y. Law Edwin W. C. Lee Sheung-Wai Law Ben K. B. Chan Phoon-Ping Chen Grace P. Y. Szeto 《Journal of occupational rehabilitation》2013,23(3):361-370
Introduction Early screening of physical and psychosocial risk factors has been advocated as a way to identify low back pain (LBP) patients who may develop chronic disability. This study evaluated the predictive validity of a Chinese version of the Orebro Musculoskeletal Pain Questionnaire (OMPQ) in identifying LBP patients at risk of developing poor return-to-work (RTW) outcomes. Methods Altogether 241 patients with acute or subacute non-specific LBP agreed to participate, and they were screened at baseline with OMPQ, and evaluated after discharge from physiotherapy (n = 173) with outcome measures including the Roland–Morris Disability Questionnaire (RMDQ), numerical pain score (0–10) and global recovery (0–10). At 1-year follow-up, information on RTW status as well as sick leave duration were obtained. Results At baseline the OMPQ had a mean score of 112.0 (SD = 26.5). The receiver operator characteristic (ROC) curves of OMPQ scores at 1-year follow-up recorded values of area under the curve of 0.693 for RTW and 0.714 for sick leave duration, which are comparable to those reported in European studies. OMPQ was the only factor that could significantly predict the RTW outcomes, compared to other variables such as the RMDQ scores. Conclusion The results confirmed the predictive validity of the Chinese version of OMPQ in screening LBP patients at risk of developing poor occupational outcomes, and appropriate interventions can be arranged for these high-risk individuals in the rehabilitation process. 相似文献
85.
86.
87.
Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor 总被引:2,自引:1,他引:2
Wuillemin WA; Minnema M; Meijers JC; Roem D; Eerenberg AJ; Nuijens JH; ten Cate H; Hack CE 《Blood》1995,85(6):1517-1526
From experiments with purified proteins, it has been concluded that factor XIa (FXIa) is inhibited in plasma mainly by alpha 1-antitrypsin (a1AT), followed by antithrombin III (ATIII), C1-inhibitor (C1Inh), and alpha 2-antiplasmin (a2AP). However, the validity of this concept has never been studied in plasma. We established the relative contribution of different inhibitors to the inactivation of FXIa in human plasma, using enzyme-linked immunosorbent assays (ELISAs) for the quantification of complexes of FXIa with a1AT, C1Inh, a2AP, and ATIII. We found that 47% of FXIa added to plasma formed complexes with C1Inh, 24.5% with a2AP, 23.5% with a1AT, and 5% with ATIII. The distribution of FXIa between these inhibitors in plasma was independent of whether FXIa was added to plasma, or was activated endogenously by kaolin, celite, or glass. However, in the presence of heparin (1 or 50 U/mL), C1Inh appeared to be the major inhibitor of FXIa, followed by ATIII. Furthermore, at lower temperatures, less FXIa-C1Inh and FXIa-a1AT complexes but more FXIa-a2AP complexes were formed. These data demonstrate that the contribution of the different inhibitors to inactivation of FXIa in plasma may vary, but C1Inh is the principal inhibitor under most conditions. 相似文献
88.
Martina Giovannella Bjrn Andresen Julie B Andersen Sahla El-Mahdaoui Davide Contini Lorenzo Spinelli Alessandro Torricelli Gorm Greisen Turgut Durduran Udo M Weigel Ian Law 《Journal of cerebral blood flow and metabolism》2020,40(10):2055
Diffuse correlation spectroscopy (DCS) can non-invasively and continuously asses regional cerebral blood flow (rCBF) at the cot-side by measuring a blood flow index (BFI) in non-traditional units of cm2/s. We have validated DCS against positron emission tomography using 15O-labeled water (15O-water PET) in a piglet model allowing us to derive a conversion formula for BFI to rCBF in conventional units (ml/100g/min). Neonatal piglets were continuously monitored by the BabyLux device integrating DCS and time resolved near infrared spectroscopy (TRS) while acquiring 15O-water PET scans at baseline, after injection of acetazolamide and during induced hypoxic episodes. BFI by DCS was highly correlated with rCBF (R = 0.94, p < 0.001) by PET. A scaling factor of 0.89 (limits of agreement for individual measurement: 0.56, 1.39)×109× (ml/100g/min)/(cm2/s) was used to derive baseline rCBF from baseline BFI measurements of another group of piglets and of healthy newborn infants showing an agreement with expected values. These results pave the way towards non-invasive, cot-side absolute CBF measurements by DCS on neonates. 相似文献
89.
Jan Kottner Janet Cuddigan Keryln Carville Katrin Balzer Dan Berlowitz Susan Law Mary Litchford Pamela Mitchell Zena Moore Joyce Pittman Dominique Sigaudo-Roussel Chang Yee Yee Emily Haesler 《Journal of tissue viability》2019,28(2):51-58
Aim
The European Pressure Ulcer Advisory Panel, the Pan Pacific Pressure Injury Alliance, and the National Pressure Ulcer Advisory Panel are updating the ‘Prevention and Treatment of Pressure Ulcers: Clinical Practice Guideline’ (CPG) in 2019. The aim of this contribution is to summarize and to discuss the guideline development protocol for the 2019 update.Methods
A guideline governance group determines and monitors all steps of the CPG development. An international survey of consumers will be undertaken to establish consumer needs and interests. Systematic evidence searches in relevant electronic databases cover the period from July 2013 through August 2018. Risk of bias of included studies will be assessed by two reviewers using established checklists and an overall strength of evidence assigned to the cumulative body of evidence. Small working groups review the evidence available for each topic, review and/or draft the guideline chapters and recommendations and/or good practice statements. Finally, strength of recommendation grades are assigned. The recommendations are rated based on their importance and their potential to improve individual patient outcomes using an international formal consensus process.Discussion
Major methodological advantages of the current revision are a clear distinction between evidence-based recommendations and good practice statements and strong consumer involvement.Conclusion
The 2019 guideline update builds on the previous 2014 version to ensure consistency and comparability. Methodology changes will improve the guideline quality to increase clarity and to enhance implementation and compliance. The full guideline development protocol can be accessed from the guideline website (http://www.internationalguideline.com/). 相似文献90.
Tai YT Dillon M Song W Leiba M Li XF Burger P Lee AI Podar K Hideshima T Rice AG van Abbema A Jesaitis L Caras I Law D Weller E Xie W Richardson P Munshi NC Mathiot C Avet-Loiseau H Afar DE Anderson KC 《Blood》2008,112(4):1329-1337
Currently, no approved monoclonal antibody (mAb) therapies exist for human multiple myeloma (MM). Here we characterized cell surface CS1 as a novel MM antigen and further investigated the potential therapeutic utility of HuLuc63, a humanized anti-CS1 mAb, for treating human MM. CS1 mRNA and protein was highly expressed in CD138-purified primary tumor cells from the majority of MM patients (more than 97%) with low levels of circulating CS1 detectable in MM patient sera, but not in healthy donors. CS1 was expressed at adhesion-promoting uropod membranes of polarized MM cells, and short interfering RNA (siRNA) targeted to CS1 inhibited MM cell adhesion to bone marrow stromal cells (BMSCs). HuLuc63 inhibited MM cell binding to BMSCs and induced antibody-dependent cellular cytotoxicity (ADCC) against MM cells in dose-dependent and CS1-specific manners. HuLuc63 triggered autologous ADCC against primary MM cells resistant to conventional or novel therapies, including bortezomib and HSP90 inhibitor; and pretreatment with conventional or novel anti-MM drugs markedly enhanced HuLuc63-induced MM cell lysis. Administration of HuLuc63 significantly induces tumor regression in multiple xenograft models of human MM. These results thus define the functional significance of CS1 in MM and provide the preclinical rationale for testing HuLuc63 in clinical trials, either alone or in combination. 相似文献